Compromized geranylgeranylation of RhoA and Rac1 in mevalonate kinase deficiency - PubMed (original) (raw)
Compromized geranylgeranylation of RhoA and Rac1 in mevalonate kinase deficiency
L Henneman et al. J Inherit Metab Dis. 2010 Oct.
Abstract
Mevalonate kinase deficiency (MKD) is an autoinflammatory disorder caused by mutations in the MVK gene resulting in decreased activity of the enzyme mevalonate kinase (MK). Although MK is required for biosynthesis of all isoprenoids, in MKD, in particular, the timely synthesis of geranylgeranyl pyrophosphate appears to be compromised. Because small guanosine triphosphatases (GTPases) depend on geranylgeranylation for their proper signaling function, we studied the effect of MK deficiency on geranylgeranylation and activation of the two small GTPases, RhoA and Rac1. We demonstrate that both geranylgeranylation and activation of the two GTPases are more easily disturbed in MKD cells than in control cells when the flux though the isoprenoid biosynthesis pathway is suppressed by low concentrations of simvastatin. The limited capacity of geranylgeranylation in MKD cells readily leads to markedly increased levels of nonisoprenylated and activated GTPases, which will affect proper signaling by these GTPases.
Figures
Fig. 1
Effect of simvastatin on the localization and activation of RhoA (a–e) and Rac1 (f–j). Control and mevalonate kinase deficient (MKD) cells were incubated with 0 (white bar; set as 100%), 0.02 (grey bar), or 0.2 μM (black bar) simvastatin for 2 days. Equal amounts of cell lysate (a, f) were analyzed for relative levels of RhoA (b) and Rac1 (g) associated with the membranes and relative soluble levels of RhoA (c) and Rac1 (h). In separate experiments, equal amounts of cell lysate (d, i) were analyzed for relative levels of active RhoA (e) and Rac1 (j). Bars show the mean and standard error of the mean (SEM) of three independent experiments. Immunoblots show the results of one representative experiment. Statistic analysis of observed effects of treatments was performed with one-way analysis of variance followed by Dunnett’s post hoc test. * = P < 0.05, ** = P < 0.01
Fig. 2
Effect of geranylgeranyltransferase inhibitor (GGTI) on the localization and activation of RhoA (a–e) and Rac1 (f–j). Control and mevalonate kinase deficient (MKD) cells were incubated with 0 μM (white bar; set as 100%) or 20 μM (black bar) GGTI for 2 days. Equal amounts of cell lysate (a, f) were analyzed for relative levels of RhoA (b) and Rac1 (g) associated with membranes and relative soluble levels of RhoA (c) and Rac1 (h). In separate experiments, equal amounts of cell lysate (d, i) were analyzed for relative levels of active RhoA (e) and Rac1 (j). Bars show the mean and standard error of the mean (SEM) of three independent experiments. Immunoblots show the results of one representative experiment. Statistic analysis of observed effects of treatments was performed with paired Student’s t test; * = P < 0.05, ** = P < 0.01
Fig. 3
Effect of simvastatin on activation of membrane-bound and soluble RhoA (a–c) and Rac1 (d–f). Control and mevalonate kinase deficient (MKD) cells were incubated with 0 (white bar), 0.02 (grey bar), or 0.2 μM (black bar) simvastatin for 2 days. Equal amounts of cell lysate (a, d) were analyzed for relative levels of active RhoA (b) and active Rac1 (e) associated with the membranes (white bar set as 100%) and relative soluble levels of active RhoA (c) and active Rac1 (f) (black bar set as 100%). Bars show the mean and standard error of the mean (SEM) of three independent experiments. Immunoblots show the results of one representative experiment. nd not detected. Statistical analysis of observed treatments effects was performed with one-way analysis of variance followed by Dunnett’s post hoc test; * = P < 0.05, ** = P < 0.01
Similar articles
- Compromised Protein Prenylation as Pathogenic Mechanism in Mevalonate Kinase Deficiency.
Politiek FA, Waterham HR. Politiek FA, et al. Front Immunol. 2021 Sep 3;12:724991. doi: 10.3389/fimmu.2021.724991. eCollection 2021. Front Immunol. 2021. PMID: 34539662 Free PMC article. Review. - Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity.
van der Burgh R, Pervolaraki K, Turkenburg M, Waterham HR, Frenkel J, Boes M. van der Burgh R, et al. J Biol Chem. 2014 Oct 3;289(40):27757-65. doi: 10.1074/jbc.M114.571810. Epub 2014 Aug 8. J Biol Chem. 2014. PMID: 25107911 Free PMC article. - Molecular and cellular consequences of mevalonate kinase deficiency.
Politiek FA, Turkenburg M, Henneman L, Ofman R, Waterham HR. Politiek FA, et al. Biochim Biophys Acta Mol Basis Dis. 2024 Jun;1870(5):167177. doi: 10.1016/j.bbadis.2024.167177. Epub 2024 Apr 16. Biochim Biophys Acta Mol Basis Dis. 2024. PMID: 38636615 - HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation.
Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, Coffer PJ. Kuijk LM, et al. Blood. 2008 Nov 1;112(9):3563-73. doi: 10.1182/blood-2008-03-144667. Epub 2008 Aug 6. Blood. 2008. PMID: 18684863 - Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation.
Normand S, Massonnet B, Delwail A, Favot L, Cuisset L, Grateau G, Morel F, Silvain C, Lecron JC. Normand S, et al. Eur Cytokine Netw. 2009 Sep;20(3):101-7. doi: 10.1684/ecn.2009.0163. Eur Cytokine Netw. 2009. PMID: 19825518 Review.
Cited by
- Defects in mitochondrial clearance predispose human monocytes to interleukin-1β hypersecretion.
van der Burgh R, Nijhuis L, Pervolaraki K, Compeer EB, Jongeneel LH, van Gijn M, Coffer PJ, Murphy MP, Mastroberardino PG, Frenkel J, Boes M. van der Burgh R, et al. J Biol Chem. 2014 Feb 21;289(8):5000-12. doi: 10.1074/jbc.M113.536920. Epub 2013 Dec 19. J Biol Chem. 2014. PMID: 24356959 Free PMC article. - Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology.
Marcuzzi A, Piscianz E, Zweyer M, Bortul R, Loganes C, Girardelli M, Baj G, Monasta L, Celeghini C. Marcuzzi A, et al. Int J Mol Sci. 2016 Mar 11;17(3):365. doi: 10.3390/ijms17030365. Int J Mol Sci. 2016. PMID: 26978350 Free PMC article. - Compromised Protein Prenylation as Pathogenic Mechanism in Mevalonate Kinase Deficiency.
Politiek FA, Waterham HR. Politiek FA, et al. Front Immunol. 2021 Sep 3;12:724991. doi: 10.3389/fimmu.2021.724991. eCollection 2021. Front Immunol. 2021. PMID: 34539662 Free PMC article. Review. - Statin use and markers of immunity in the Doetinchem cohort study.
De Jong HJ, Damoiseaux JG, Vandebriel RJ, Souverein PC, Gremmer ER, Wolfs M, Klungel OH, Van Loveren H, Cohen Tervaert JW, Verschuren WM. De Jong HJ, et al. PLoS One. 2013 Oct 16;8(10):e77587. doi: 10.1371/journal.pone.0077587. eCollection 2013. PLoS One. 2013. PMID: 24147031 Free PMC article. - Mevalonate kinase-deficient THP-1 cells show a disease-characteristic pro-inflammatory phenotype.
Politiek FA, Turkenburg M, Ofman R, Waterham HR. Politiek FA, et al. Front Immunol. 2024 Mar 14;15:1379220. doi: 10.3389/fimmu.2024.1379220. eCollection 2024. Front Immunol. 2024. PMID: 38550596 Free PMC article.
References
- Ando S, Kaibuchi K, Sasaki T, et al. Post-translational processing of rac p21s is important both for their interaction with the GDP/GTP exchange proteins and for their activation of NADPH oxidase. J Biol. Chem. 1992;267:25709–25713. - PubMed
- Carlucci F, Rosi F, Di PC, Marinello E, Pizzichini M, Tabucchi A. Purine nucleotide metabolism: specific aspects in chronic lymphocytic leukemia lymphocytes. Biochim Biophys. Acta. 1997;1360:203–210. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials